Elevation Oncology (ELEV)
(Delayed Data from NSDQ)
$2.93 USD
+0.04 (1.38%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.94 +0.01 (0.34%) 4:24 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ELEV 2.93 +0.04(1.38%)
Will ELEV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELEV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ELEV
Are Medical Stocks Lagging Elevation Oncology (ELEV) This Year?
ELEV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELEV
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
Elevation Oncology (ELEV) Receives a Buy from TD Cowen
Elevation Oncology’s EO-3021: A Promising Candidate in the Treatment Landscape for GEJ and GC
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
Elevation Oncology to evaluate combination in gastroesophageal junction cancer